Keybanc analyst Philip Gibbs downgrades TimkenSteel (NYSE:TMST) from Overweight to Sector Weight.
SVB Leerink Maintains Outperform on Viridian Therapeutics, Raises Price Target to $40
SVB Leerink analyst Mike Kratky maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $32 to $40.